Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy

J Neurooncol. 2018 Sep;139(3):779-780. doi: 10.1007/s11060-018-2902-9. Epub 2018 May 18.

Authors

Carmen Balana¹, Anna Estival², Estela Pineda³

Affiliations

¹ Catalan Institute of Oncology, Ctra Canyet s/n, 08916, Badalona, Spain. cbalana@iconcologia.net.
² Catalan Institute of Oncology, Ctra Canyet s/n, 08916, Badalona, Spain.
³ Hospital Clinic de Barcelona, Barcelona, Spain.

PMID: 29777419
DOI: 10.1007/s11060-018-2902-9

No abstract available

Publication types

Letter

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Bevacizumab / therapeutic use*
Brain Neoplasms / drug therapy*
Brain Neoplasms / pathology
Glioblastoma / drug therapy*
Glioblastoma / pathology
Humans
Prognosis
Retreatment

Substances

Angiogenesis Inhibitors
Bevacizumab